Search Results
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 3
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 4
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 1
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Session 2
Minimal Residual Disease as a Surrogate Endpoint in Hematologic Cancer Trials: Opening Remarks
Use of Surrogate Endpoints in Oncology
Friends of Cancer Research Annual Meeting 2024
MRD as a surrogate endpoint: what remains for FDA approval?
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Minimal Residual Disease (MRD) Overview | LRF Ed Forum Series
Key Takeaway Points in Phase III ALCYONE Trial for Multiple Myeloma
MRD in solid tumor and hematological indications: today and tomorrow
